Emerging targets for the treatment of scleroderma

Bibliography

• Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005;26:596-602
   PubMed Web of Science ®Google Scholar
• Shand L, Lunt M, Nihtyanova S, Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007l;56(7):2422-31
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Tang EC, Coghlan JG, Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010;103(2):109-15
   PubMed Web of Science ®Google Scholar
• Denton CP. Renal manifestations of systemic sclerosis–clinical features and outcome assessment. Rheumatology (Oxford) 2008;47(Suppl 5):v54-6
   PubMedGoogle Scholar
• Kowal-Bielecka O, Landewe R, Avouac J, EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5):620-8
   PubMed Web of Science ®Google Scholar
• Walker KM, Pope J; Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38(7):1326-8
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54(12):3962-70
   PubMed Web of Science ®Google Scholar
• Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10(5):R124
   PubMed Web of Science ®Google Scholar
• Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10(5):248-55
   PubMed Web of Science ®Google Scholar
• Herrick AL, Lunt M, Whidby N, Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010;37(1):116-24
   PubMed Web of Science ®Google Scholar
• Kirk TZ, Mark ME, Chua CC, Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995;270(7):3423-8
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Chen Y, Denton CP, Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15(6):2707-19
   PubMed Web of Science ®Google Scholar
• Chen Y, Shi-Wen X, van Beek J, Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;167(6):1699-711
   PubMed Web of Science ®Google Scholar
• Rajkumar VS, Howell K, Csiszar K, Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005;7(5):R1113-23
   PubMed Web of Science ®Google Scholar
• Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007;9(Suppl 2):S4
   PubMed Web of Science ®Google Scholar
• Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008;20(8):1409-14
   PubMed Web of Science ®Google Scholar
• Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011;10(5):267-75
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6
   PubMed Web of Science ®Google Scholar
• Milano A, Pendergrass SA, Sargent JL, Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008;3(7):e2696
   PubMed Web of Science ®Google Scholar
• Pendergrass SA, Lemaire R, Francis IP, Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies.. J Invest Dermatol 2012; doi: 10.1038/jid.2011.472
   PubMed Web of Science ®Google Scholar
• Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999;117(2):207-8
   PubMed Web of Science ®Google Scholar
• Padula SJ, Clark RB, Korn JH. Cell-mediated immunity in rheumatic disease. Hum Pathol 1986;17(3):254-63
   PubMed Web of Science ®Google Scholar
• Aden N, Shiwen X, Aden D, Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology (Oxford) 2008;47(12):1754-60
   PubMed Web of Science ®Google Scholar
• Aden N, Nuttall A, Shiwen X, Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol 2010;130(9):2191-200
   PubMed Web of Science ®Google Scholar
• Oikonomou N, Harokopos V, Zalevsky J, Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One 2006;1:e108
   PubMed Web of Science ®Google Scholar
• Oga T, Matsuoka T, Yao C, Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 2009;15(12):1426-30
   PubMed Web of Science ®Google Scholar
• Sudo K, Yamada Y, Moriwaki H, Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 2005;29(5):236-44
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Lasky J, Lungarella G, Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999;20(4):825-33
   PubMed Web of Science ®Google Scholar
• McCann MR, Monemdjou R, Ghassemi-Kakroodi P, mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther 2011;13(1):R6
   PubMedGoogle Scholar
• Stratton R, Shiwen X. Role of prostaglandins in fibroblast activation and fibrosis. J Cell Commun Signal 2010;4(2):75-7
   PubMedGoogle Scholar
• Walker NM, Badri LN, Wadhwa A, Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med 2012;85(1):77-84
   Google Scholar
• Dackor RT, Cheng J, Voltz JW, Prostaglandin E2 protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol 2011;301(5):L645-55
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu Y, Zhou W, A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res 2010;11:34
   PubMedGoogle Scholar
• Verrecchia F, Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 2004;16(8):873-80
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Shiwen X, Black CM, Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000;275(20):15220-5
   PubMed Web of Science ®Google Scholar
• Stratton R, Shiwen X, Martini G, Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108(2):241-50
   PubMed Web of Science ®Google Scholar
• Stratton R, Newton F. Commentary on a recent article-"A prostacyclin analogue, Iloprost, protects from bleomycin-induced fibrosis in mice" Zhu Y et al. Respir Res 2010 Mar 20;11(1):34. J Cell Commun Signal 2010;4(4):187-8
   PubMedGoogle Scholar
• Koca SS, Isik A, Ozercan IH, Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 2008;47(2):172-5
   PubMed Web of Science ®Google Scholar
• Distler JH, Jordan S, Airo P, Is there a role for TNFalpha antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 2011;29(2 Suppl 65):S40-5
   PubMed Web of Science ®Google Scholar
• Mayes MD. The Scleroderma Book. Oxford University Press; Oxford: 1999
   Google Scholar
• Denton CP, Merkel PA, Furst DE, Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33
   PubMed Web of Science ®Google Scholar
• Seibold JR, Denton CP, Furst DE, Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62(7):2101-8
   PubMed Web of Science ®Google Scholar
• Greenblatt MB, Sargent JL, Farina G, Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012;180(3):1080-94
   PubMed Web of Science ®Google Scholar
• Fleming JN, Shulman HM, Nash RA, Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One 2009;4(7):e6203
   PubMed Web of Science ®Google Scholar
• Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol 2008;20(5):601-7
   PubMed Web of Science ®Google Scholar
• Dorner T, Lipsky PE. Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol 2006;305:213-40
   PubMed Web of Science ®Google Scholar
• Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-27
   PubMed Web of Science ®Google Scholar
• Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56(9):3167-8
   PubMed Web of Science ®Google Scholar
• Whitfield ML, Finlay DR, Murray JI, Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100(21):12319-24
   PubMed Web of Science ®Google Scholar
• Yoshizaki A, Iwata Y, Komura K, CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008;172(6):1650-63
   PubMed Web of Science ®Google Scholar
• Leask A. B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal 2010;4(4):201-2
   PubMedGoogle Scholar
• Lafyatis R, Kissin E, York M, B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60(2):578-83
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49(2):271-80
   PubMed Web of Science ®Google Scholar
• Smith V, Van Praet JT, Vandooren B, Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010;69(1):193-7
   PubMed Web of Science ®Google Scholar
• Bosello S, De Santis M, Lama G, B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010;12(2):R54
   PubMed Web of Science ®Google Scholar
• Hirano T, Kishimoto T. Interleukin 6 and plasma cell neoplasias. Prog Growth Factor Res 1989;1(3):133-42
   PubMedGoogle Scholar
• Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62(1 Pt 2):S60-5
   PubMedGoogle Scholar
• Koch AE, Kronfeld-Harrington LB, Szekanecz Z, In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61(5-6):239-46
   PubMed Web of Science ®Google Scholar
• Kadono T, Kikuchi K, Ihn H, Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25(2):296-301
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1 from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27(2):140-6
   PubMed Web of Science ®Google Scholar
• Bolster MB, Ludwicka A, Sutherland SE, Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997;40(4):743-51
   PubMed Web of Science ®Google Scholar
• Schmidt K, Martinez-Gamboa L, Meier S, Bronchoalveolar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009;11(4):R111
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H, The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49(12):2408-12
   PubMed Web of Science ®Google Scholar
• Geyer M, Muller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol 2010;22(3):246-51
   PubMed Web of Science ®Google Scholar
• Vonk MC, Marjanovic Z, van den Hoogen FH, Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008;67:98-104
   PubMed Web of Science ®Google Scholar
• Fleming JN, Nash RA, McLeod DO, Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 2008;3:e1452
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Laboureau J, Verola O, Skin involvement in scleroderma: where histological and clinical scores meet. Rheumatology (Oxford) 2007;46:833-41
   PubMed Web of Science ®Google Scholar
• Nash RA, McSweeney PA, Crofford LJ, High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007;110:1388-96
   PubMed Web of Science ®Google Scholar